30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler

RxCUI: 1539251
RxNorm name: 30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler
Display name: 30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler
Full name: 30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:23

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Umeclidinium Ellipta	UMECLIDINIUM	Prasco Laboratories	763388a5-cc89-4c25-8562-521df679b7e8	2025-11-06	Warnings, Adverse reactions	Exact identifier rxcui: 1539251
Incruse Ellipta	UMECLIDINIUM	GlaxoSmithKline LLC	dbb64747-1505-49d7-9a33-99dd402e96d3	2023-12-13	Warnings, Adverse reactions	Exact identifier rxcui: 1539251

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
dbb64747-1505-49d7-9a33-99dd402e96d3	30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler	SCD	27	These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE ELLIPTA (umeclidinium inhalation powder), for oral inhalation use Initial U.S. Approval: 2013	20231213
dbb64747-1505-49d7-9a33-99dd402e96d3	umeclidinium 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters	PSN	27	These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE ELLIPTA (umeclidinium inhalation powder), for oral inhalation use Initial U.S. Approval: 2013	20231213
dbb64747-1505-49d7-9a33-99dd402e96d3	umeclidinium 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters	SY	27	These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE ELLIPTA (umeclidinium inhalation powder), for oral inhalation use Initial U.S. Approval: 2013	20231213
763388a5-cc89-4c25-8562-521df679b7e8	umeclidinium 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters	PSN	2	These highlights do not include all the information needed to use Umeclidinium ELLIPTA safely and effectively. See full prescribing information for Umeclidinium ELLIPTA. Umeclidinium ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013	20251106
763388a5-cc89-4c25-8562-521df679b7e8	umeclidinium 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters	SY	2	These highlights do not include all the information needed to use Umeclidinium ELLIPTA safely and effectively. See full prescribing information for Umeclidinium ELLIPTA. Umeclidinium ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013	20251106
763388a5-cc89-4c25-8562-521df679b7e8	30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler	SCD	2	These highlights do not include all the information needed to use Umeclidinium ELLIPTA safely and effectively. See full prescribing information for Umeclidinium ELLIPTA. Umeclidinium ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013	20251106